PIP2 at the Core of Aβ Oligomers’ Synaptic Attack?
Perhaps no topic is hotter in Alzheimer disease molecular research today than the synaptic effects of amyloid-β (Aβ) oligomers...
6390 RESULTS
Sort By:
Perhaps no topic is hotter in Alzheimer disease molecular research today than the synaptic effects of amyloid-β (Aβ) oligomers...
To borrow IT-speak, “repurposing” is an underused art in Alzheimer disease drug research...
Antibody therapies for AD have galvanized researchers and affected families and observers from academia, industry, and even the investment community...
Eight years ago, JoAnne McLaurin’s research suggested that a particular stereoisomer of a inositol sugar alcohol might make a respectable AD drug...
The cholinergic hypothesis of Alzheimer disease tends to elicit a yawn from scientists who reserve their excitement for anti-amyloid treatments...
At the Alzheimer’s disease Keystone Symposium, held 24-29 March in Keystone, Colorado, a spate of news on potential future treatments capped a week of presentations...
Enlisting the immune system to fight Alzheimer disease can take the form of immunization against Aβ, or other attempts to modulate the inflammatory response that plays a role in disease...
The birth of new neurons in the adult brain intimates a capacity for restoration even in the face of aging and neurodegeneration...
Alzheimer Activism: How To Modernize Clinical Trials? Measures of Clinical Meaningfulness—An AD Ally/FDA Scientific Workshop
How long a cell survives often depends on just how sturdy its defenses are against reactive oxygen species...
On March 13, Alzheimer disease activist groups met with representatives from the FDA, clinicians, and industry leaders to discuss ways to improve clinical trials for candidate AD drugs...
For a worm, just a few neurons are sufficient to hold a lifetime of memories, making this simple organism an attractive model for learning about learning...
Researchers report that RAGE mediates the toxic effects of Aβ oligomers in entorhinal cortex neurons...
The sixth annual Drug Discovery for Neurodegeneration meeting convened in Washington, DC, on 4-5 February...
This is the second and final part of our coverage of the Drug Discovery for Neurodegeneration meeting, held in Washington, DC, on 4-5 February...